Cargando…
The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023086/ https://www.ncbi.nlm.nih.gov/pubmed/35465974 http://dx.doi.org/10.1016/j.jaci.2022.03.026 |
| _version_ | 1784690257273290752 |
|---|---|
| author | Miller, Aaron L. Rider, Nicholas L. Pyles, Richard B. Judy, Barbara Xie, Xuping Shi, Pei-Yong Ksiazek, Thomas G. |
| author_facet | Miller, Aaron L. Rider, Nicholas L. Pyles, Richard B. Judy, Barbara Xie, Xuping Shi, Pei-Yong Ksiazek, Thomas G. |
| author_sort | Miller, Aaron L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9023086 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | American Academy of Allergy, Asthma & Immunology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90230862022-04-22 The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin Miller, Aaron L. Rider, Nicholas L. Pyles, Richard B. Judy, Barbara Xie, Xuping Shi, Pei-Yong Ksiazek, Thomas G. J Allergy Clin Immunol Covid-19 American Academy of Allergy, Asthma & Immunology 2022-06 2022-04-22 /pmc/articles/PMC9023086/ /pubmed/35465974 http://dx.doi.org/10.1016/j.jaci.2022.03.026 Text en © 2022 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Covid-19 Miller, Aaron L. Rider, Nicholas L. Pyles, Richard B. Judy, Barbara Xie, Xuping Shi, Pei-Yong Ksiazek, Thomas G. The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| title | The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| title_full | The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| title_fullStr | The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| title_full_unstemmed | The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| title_short | The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| title_sort | arrival of sars-cov-2–neutralizing antibodies in a currently available commercial immunoglobulin |
| topic | Covid-19 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023086/ https://www.ncbi.nlm.nih.gov/pubmed/35465974 http://dx.doi.org/10.1016/j.jaci.2022.03.026 |
| work_keys_str_mv | AT milleraaronl thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT ridernicholasl thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT pylesrichardb thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT judybarbara thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT xiexuping thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT shipeiyong thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT ksiazekthomasg thearrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT milleraaronl arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT ridernicholasl arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT pylesrichardb arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT judybarbara arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT xiexuping arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT shipeiyong arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin AT ksiazekthomasg arrivalofsarscov2neutralizingantibodiesinacurrentlyavailablecommercialimmunoglobulin |